版本:
中国

BRIEF-TherapeuticsMD receives complete response letter from FDA for TX-004hr NDA

May 8 Therapeuticsmd Inc

* Therapeuticsmd receives complete response letter from fda for tx-004hr new drug application

* Therapeuticsmd inc - no approvability issues identified by fda related to efficacy or cmc

* Therapeuticsmd inc - crl did not identify any issues related to efficacy of tx-004hr

* Therapeuticsmd inc - no cases of endometrial hyperplasia were observed in rejoice trial at end of week 12 for all doses studied and included in nda

* Therapeuticsmd-Concern raised by fda was lack of long-term endometrial safety data for tx-004hr beyond 12-weeks studied in pivotal phase 3 rejoice trial

* Therapeuticsmd - crl did not identify issues related to efficacy of tx-004hr, did not identify approvability issues related to chemistry and controls

* Therapeuticsmd inc - co believes that nda was approvable as filed and intends to meet with fda as soon as possible to address concerns raised by fda

* Therapeuticsmd-Continuing to prepare nda for tx-001hr and anticipate that co will submit that nda to fda as early as q3 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐